CCP has recovered Rs40 million from UDPL and IBL after a tribunal upheld penalties over a non-compete deal that restricted pharmaceutical distribution competition under the Competition Act, 2010.
What CCP Recovered and Why the Case Matters
The Competition Commission of Pakistan (CCP) has recovered a total penalty of Rs. 40 million from two companies—United Distributors Pakistan Limited (UDPL) and International Brands (Private) Limited (IBL). The fines relate to an anti-competitive non-compete agreement that CCP said violated Section 4 of the Competition Act, 2010.
This matters because non-compete agreements can sometimes be legitimate, but when they are used to remove a competitor from a market in exchange for money, they can become a form of market sharing. In Pakistan’s competition law framework, agreements that restrict competition, reduce consumer choice, or distort market dynamics can trigger enforcement action.
The recovery also signals something important: this is not only a “paper order.” CCP is showing it can enforce penalties, especially after its decision has been upheld through the appeals process.
What the Tribunal Upheld: A Prohibited Market-Sharing Arrangement
The enforcement action followed the Competition Appellate Tribunal (CAT) upholding CCP’s decision. The Tribunal affirmed CCP’s findings that the agreement between UDPL and IBL amounted to a prohibited market-sharing arrangement that restricted competition in the relevant market.
In competition terms, market sharing happens when firms agree to divide markets, customers, products, or territories in a way that reduces rivalry. Even if the agreement is framed as a “non-compete,” the legal and economic test focuses on the effect: does it remove competitive pressure and block normal market entry and expansion?
By upholding the penalties, the Tribunal reinforced the legality of CCP’s decision and strengthened CCP’s ability to enforce compliance in similar cases in the future.
How the Agreement Worked: Rs1.131 Billion for a Three-Year Exit
The case started after UDPL disclosed to the Pakistan Stock Exchange that it had entered into a non-compete agreement with IBL. Under the arrangement, UDPL agreed not to distribute human pharmaceutical products in Pakistan for three years. In return, IBL agreed to pay PKR 1.131 billion.
CCP concluded that the payment was effectively a financial incentive to secure UDPL’s exit from competition in the relevant market. In plain terms, instead of competing through better service, pricing, or distribution capability, the deal paid a market player to step away.
CCP said this reduced competitive pressure, distorted market dynamics, and created barriers to entry. In distribution markets—especially pharma—competition matters because it can influence availability, service levels, and cost structures throughout the supply chain. Removing a distributor through a paid non-compete can reduce options for manufacturers and can indirectly affect consumers.
Why CCP Rejected Exemption Claims and Imposed Penalties
Although the agreement reportedly included a clause that required regulatory approval, both companies failed to obtain prior exemption from CCP. Instead, they submitted applications only after CCP issued show-cause notices. CCP rejected the exemption request, stating that the agreement did not meet the statutory criteria and that the violation had already occurred.
As a result, CCP imposed a penalty of PKR 20 million on each company under Section 38 of the Competition Act, 2010, for entering into and implementing the anti-competitive agreement. The Tribunal’s decision upheld these penalties, which is why CCP was able to proceed with recovery.
The core compliance lesson for businesses is clear: if an agreement has competition risks, seeking approval or exemption after implementation is usually too late. Competition regulators often look at timing, intent, and market impact. Once an anti-competitive effect has started, the legal exposure can already be triggered.
What This Signals for Businesses: Stronger Enforcement on Competition Deals
This recovery highlights CCP’s continued push to enforce competition law against agreements that distort markets. For companies, the case is a warning that large “exit payments” tied to non-compete commitments can be treated as anti-competitive, especially when they remove an active competitor from a market for a fixed period.
It also shows the importance of governance and legal review before signing major commercial agreements. Businesses should assess whether a non-compete is genuinely necessary, narrow in scope, and pro-competitive in effect—or whether it functions as a market allocation tool.
For the wider economy, enforcement actions like this can support healthier competition by discouraging private deals that reduce rivalry. Stronger competition can improve efficiency, encourage investment, and reduce the risk of price or supply distortions that ultimately hurt consumers.
In short, CCP’s message is that competition compliance is not optional, and even well-funded agreements can face penalties if their main effect is to restrict competition.
